Hemovent GmbH – Trademark Portfolio
Entity Type: 27
Hemovent GmbH holds 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 41 (Education & Entertainment) — 11 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 4 Nice Classification classes. Currently, 7 trademarks are registered and 1 is pending. Notable registered marks include BLYZZ, MOBYO, WATCHA, BLYZZEE, and MOBYBOX. The owner is based in Aachen.
Pascalstraße 59
Aachen 52076 , DE
Showing of trademarks Trademarks
Trademark Classifications
Hemovent GmbH's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Education; providing of training; entertainment; sporting and cultural activities
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does Hemovent GmbH have?
Hemovent GmbH has 11 U.S. trademarks filed with the USPTO. Of these, 7 registered, 1 pending, 2 abandoned, 1 cancelled.
What trademark classes does Hemovent GmbH file in?
Hemovent GmbH files trademarks across 4 Nice Classification classes. The most active classes are Class 41 (Education & Entertainment), Class 44 (Medical Services), Class 10 (Medical Apparatus), Class 35 (Advertising & Business). Class 41 covers education; providing of training; entertainment; sporting and cultural activities.
What are Hemovent GmbH's most well-known trademarks?
Hemovent GmbH's registered trademark portfolio includes well-known marks such as BLYZZ, MOBYO, WATCHA, BLYZZEE, and MOBYBOX. These are among 7 currently registered trademarks in the portfolio.
What is Hemovent GmbH's trademark registration success rate?
Hemovent GmbH has a 70% trademark registration rate, with 7 out of 10 resolved applications resulting in successful registration. Currently, 1 application is pending review.